Insulin-Like Growth Factor Receptor  by Blumenschein, George
Insulin-Like Growth Factor Receptor
George Blumenschein, Jr, MD
The insulin-like growth factor (IGF) signaling axis plays anessential role in the balance between cellular proliferation
and apoptosis. Higher levels of IGF receptor are seen in lung
tumor cells than normal tissue. IGF-1 receptor (IGFR-1R)
and its ligand IGF-2 is overexpressed in non-small cell lung
cancer (NSCLC). Elevated levels of IGF-1 in plasma are
associated with an increased risk of developing lung cancer,
and IGF-1R has been shown to promote the proliferation of lung
cancer cells in vitro.1 IGF-1R can hybridize with other mem-
brane receptors leading to the activation of different tyrosine
kinase domains.2 The central role that the IGFR pathway plays
in various signaling pathways in tumor cells makes the IGF axis
an attractive target for therapeutic intervention.
Dr. Pollak presented an overview of the science of the
IGFR to establish the rationale for the development of this
class of drugs for the treatment of NSCLC. There are a
number of possible avenues through which the effects of IGF
can be inhibited. These strategies include antibodies directed
against IGF ligand, IGF-1R tyrosine kinase inhibitors, and
antibodies targeting the IGF-1R. The approach of blocking
the IGF-1 receptor tyrosine kinase pathway and the insulin
receptor (IR) via signal transduction inhibitors is also under-
going clinical evaluation.
IMC-A12
IMC-A12 is a fully humanized IgG1 monoclonal anti-
body with a half-life of 15 to 21 days that targets the IGF-1
receptor.3 Both weekly and q21-day schedules are being
explored. There are three ongoing randomized phase II trials
with different first-line platinum-based regimens including a trial
that is comparing gemcitabine, carbopatin with the addition of
IMC-A12, cetuximab, or both, and another evaluating carbopla-
tin, paclitaxel bevacizumab with or without IMC-A12 in nons-
quamous NSCLC. There is one randomized first-line trial of
etoposide, cisplatin with or without either IMC-A12 or the
hedgehog inhibitor GDC-0449 in extensive disease small cell
lung cancer (EDSCLC). The combination of erlotinib plus A12
was closed due to toxicity of the combination. Currently, no
additional toxicity or efficacy data are available.
AMG-479
Phase I studies established thrombocytopenia as the
dose-limiting toxicity of AMG-479, a fully human monoclo-
nal antibody to IGF-1R.4 AMG-479 is being evaluated in the
front-line setting in combination with etoposide and carbo-
platin or cisplatin in a randomized phase I/II trial in patients
with EDSCLC. Patients will receive up to six cycles of the
combination then single-agent AMG 479 as maintenance
therapy until disease progression. Preliminary results indicate
that AMG-479 can be safely combined with etoposide and
cisplatin (or carboplatin) in this patient population without
impact on the delivery of AMG-479 or the chemotherapy.
Activity in the phase I portion was similar to reported with
chemotherapy alone.5 The phase II portion of the trial has
completed accrual and results are pending.
MK-0646
MK-0646 is a fully humanized monoclonal IgG1 anti-
body that selectively binds to the IGF-1 receptor and not to
the insulin receptor.6 The recommended phase II dose is 10
mg/kg weekly. An overview of the compound and the design
of several clinical trials were presented. In the randomized
phase II IMPACT study, MK-0646 is being evaluated in
combination with pemetrexed (500 mg/m2) and cisplatin (75
mg/m2) as first-line therapy in patients with stage IIIB or IV
nonsquamous NSCLC. The phase I/II design of MK-0646
plus cisplatin and etoposide in patients with treatment-naive
EDSCLC was also presented. Both studies are ongoing but
not actively recruiting participants.
OSI-906
Phase I studies of OSI-906, an oral tyrosine kinase
inhibitor of IGF-1R and IR established a continuous daily
dosing (150 mg twice daily or 400 mg daily) and an inter-
mittent schedule (600 mg 1 week on/1 week off as part of a
2-week cycle) for further exploration in the phase II setting.
Subsequently, a phase I clinical trial combining OSI-906
with erlotinib for patients with refractory NSCLC was com-
pleted. This trial established OSI-906 150 mg BID with erlotinib
at 150 mg daily as the phase II dose. Two patients with NSCLC
had partial responses on this regimen. The common adverse
events reported included rash, hyperglycemia, diarrhea, and
fatigue.7 This combination of OSI-906 plus erlotinib is being
evaluated in ongoing randomized phase II trials including a
front-line therapy trial for patients with EGFR mutation positive
metastatic NSCLC who receive erlotinib with or without the
addition of OSI-906. A second trial explores the role of OSI-906
as maintenance therapy in patients with metastatic NSCLC who
do not have progression of disease after completing four cycles
of first-line platinum-based chemotherapy and are then random-
ized to either erlotinib or erlotinib plus OSI-906.
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BMS-754807, a oral dual kinase reversible inhibitor of
IR and IGF-1R. Preliminary phase I results indicate that the
drug is well tolerated as a single agent with common adverse
events including diarrhea, constipation, nausea, vomiting, and
fatigue.8 The ongoing phase I combination trial has demon-
strated that BMS-745807 can be safely administered with
carboplatin and paclitaxel with no reported DLTs to date.9
Additional clinical trials with BMS-754807 as a single agent
or in combination with various agents (cetuximab, herceptin,
carboplatin, and paclitaxel) in solid tumors are underway.
Future Directions
There are a number of agents targeting the IGF signal-
ing pathway in development for use in the treatment of
NSCLC. In regards to the IGF-1R monoclonal antibodies,
there has been a worrisome safety and efficacy signal from
the phase III trial of the combination of figitumumab, carbo-
platin, and paclitaxel in patients with squamous cell cancer of
the lung.10 Nevertheless, there have been no new safety
signals to date from the other molecules in this class.
The potential role of IGFR tyrosine kinase inhibitors
remains to be defined as this class of compound is in an
earlier stage of development and there is little clinical data
regarding toxicity or efficacy. Going forward, develop-
ment of compounds targeting the IGF pathway is likely to
be in combination with other agents, either with cytotoxic
chemotherapy or rational combinations with other biologic
therapies. Improvements in our understanding of molecu-
lar markers and the role of the IGFR signaling pathway
in different tumor histologies will also help us to best use
this class of compounds toward improving outcomes for
patients.
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